BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Caspase-1 (CASP1)

...and hepatitis B virus (HBV). TARGET/MARKER/PATHWAY: Caspase-1 (CASP1) LICENSING STATUS: Patent application filed; licensed to iVeena Pharmaceuticals Inc....
BioCentury | May 17, 2012
Cover Story

Eyeing the inflammasome

...it to treat wet AMD. The approach for treating dry AMD has been licensed to iVeena Pharmaceuticals Inc....
...vitreous and aqueous samples from living patients with varying stages of AMD," he said. Meanwhile, iVeena Pharmaceuticals...
...Medicine of Case Western Reserve University , Cleveland, Ohio Harvard Medical School , Boston, Mass. iVeena Pharmaceuticals Inc....
BioCentury | May 17, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

...in the mice, a peptide-based MYD88 inhibitor prevented Alu RNA-induced retinal damage. Next steps at iVeena Pharmaceuticals Inc....
Items per page:
1 - 3 of 3
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Caspase-1 (CASP1)

...and hepatitis B virus (HBV). TARGET/MARKER/PATHWAY: Caspase-1 (CASP1) LICENSING STATUS: Patent application filed; licensed to iVeena Pharmaceuticals Inc....
BioCentury | May 17, 2012
Cover Story

Eyeing the inflammasome

...it to treat wet AMD. The approach for treating dry AMD has been licensed to iVeena Pharmaceuticals Inc....
...vitreous and aqueous samples from living patients with varying stages of AMD," he said. Meanwhile, iVeena Pharmaceuticals...
...Medicine of Case Western Reserve University , Cleveland, Ohio Harvard Medical School , Boston, Mass. iVeena Pharmaceuticals Inc....
BioCentury | May 17, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

...in the mice, a peptide-based MYD88 inhibitor prevented Alu RNA-induced retinal damage. Next steps at iVeena Pharmaceuticals Inc....
Items per page:
1 - 3 of 3